(Q37293519)

English

Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy.

scientific article published on October 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Europe PubMed Central

Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

T Seshadri

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

J Stakiw

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Pintilie

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Crump

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

J Kuruvilla

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 October 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

261-266

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1179%2F102453308X343527

21 January 2018

Identifiers

10.1179/102453308X343527

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18854087%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37293519&oldid=2174746714"